Document is current
Any future updates will be listed below
-
Authors
Peltoniemi, Martta
Imlimthan, Surachet
Jalonen, Sonja C.
Persson, Niklas Daniel Åke
Lohela, Terhi J.
Lilius, Tuomas O. https://orcid.org/0000-0002-8361-3683
Sarparanta, Mirkka https://orcid.org/0000-0002-2956-4366
-
Funding
Funding for this research was provided by:
Academy of Finland (318422)
Academy of Finland (346122)
Academy of Finland (350371)
Sigrid Juséliuksen Säätiö
Paulon Säätiö
Orionin Tutkimussäätiö
Suomen Kulttuurirahasto
Suomen Lääketieteen Säätiö
Emil Aaltosen Säätiö
Alfred Kordelinin Säätiö (220147)
Helsingin Yliopisto
University of Helsinki
- License Information
-
More Information
Article History
Received: 27 May 2025
Accepted: 22 June 2025
First Online: 6 July 2025
Declarations
:
: Animal experiments were carried out under project license numbers ESAVI/9782/2022, ESAVI/36258/2020, and ESAVI/4935/2024 approved by the Regional State Administrative Agency of Southern Finland (Hämeenlinna, Finland), and compliance with the respective Finnish and EU regulations and guidelines. We used the ARRIVE checklist when writing our report (Percie du Sert N, Hurst V, Ahluwalia A et al. The ARRIVE Guidelines 2.0: updated guidelines for reporting animal research).
: Not applicable.
: Tuomas Lilius is listed in a patent (patent number 20220280423) describing glymphatic-assisted drug delivery.
